Skip to main content
Future Journal of Pharmaceutical Sciences

Table 5 Comparison between quantitative assay of ROS generation induced by harmine by DCFH-DA in HeLa cell lines through Flow cytometric analysis

From: Pharmaceutical efficacy of harmalol in inhibiting hepatocellular carcinoma

Percent ROSa, b, *

Control

Harmalol post-treated

DEN

DEN+CCl4

21.3 ± 0.9

28.6 ± 0.8

71.4 ± 0.8

85.4 ± 0.7

  1. aAverage of three individual experiments at the same conditions
  2. bvalues represented means ±SD
  3. *Significantly different from the control groups (p < 0.05)
Back to article page